[Adalimumab for treating rheumatoid arthritis]
Department of Science and Technology - Brazilian Health Technology Assessment General Coordination
Record ID 32006001475
To evaluate the effectiveness and safety of isolated adalimumab or adalimumab combined together with other DMARD in the treatment of rheumatoid arthritis.
Authors' recomendations: Doses of 20mg or 40mg of subcutaneous adalimumab lasting 24 to 26 weeks, as compared to placebo, in patients with rheumatoid arthritis, are effective in the following outcomes: ACR 20/50/, number of joints with edema and pain, auto-reported visual pain analog scale, global physical assessment both autoreported and by the physician as well as quality of life. Semimonthly doses of 40mg of subcutaneous adalimumab in patients with rheumatoid arthritis were more effective than 20mg in the following outcomes at regimens of 24 to 26 weeks: ACR 20/50/ and number of joints with edema. It is advisable to prescribe adalimumab only after unsuccessful current approaches such as either isolated or combined disease modifying antirheumatic drugs (methotrexate, leflunomide, chloroquine,sulfasalazine). Longerlasting randomized conrolled trials are necessary to allow more accurate information about its effectiveness, safety and residual effects.
Project Status: Completed
URL for project: http://portal.saude.gov.br/portal/arquivos/pdf/adalimumab_for_rheumatoid_arthritis.pdf
Year Published: 2006
URL for published report: http://portal2.saude.gov.br/rebrats/visao/estudo/detEstudo.cfm?codigo=174&evento=6&v=true
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis, Rheumatoid
Organisation Name: Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
Contact Address: Ministerio da Saude, Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia, Esplanada dos Ministerios, Edificio sede; bl "G" - 8 andar - SL 834, CEP: 70058-900, Brasilia, DF Brazil, Tel: +55 61 3315 3197 Fax: +55 61 3315 3850
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: Department of Science and Technology - Brazilian Health Technology Assessment General Coordination (DECIT-CGATS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.